INnate Intramedullary Threaded Nail Milestone: 5,000 Metacarpal Fractures Successfully Treated Reports ExsoMed

INnate Intramedullary Threaded Nail: To date, 5,000 metacarpal fractures have been successfully treated reports ExsoMed Corporation. This milestone reflects the rapid adoption of ExsoMed’s technology, which is quickly becoming the new standard for metacarpal fracture fixation.

INnate Intramedullary Threaded Nail: INnate is an intramedullary threaded nail designed specifically for minimally invasive fixation of metacarpal fractures. The robust length offering with innovative dual crest height design provides optimal fit within the intramedullary canal to create stable fixation and precise reduction. INnate is the only non-compression option, constructed to avoid shortening of oblique and comminuted fractures, while providing simple fracture stabilization in minutes. All instrumentation is sterile-packed and single-use, for stream-lined use in the operating room.

“The ability to treat metacarpal fractures with INnate and the intramedullary technique has been an incredible value-add to the care of my patients,” said Marc Richard, MD (Duke University Medical Center, Durham, NC). “I have been able to expand my indications for the nails and achieve excellent outcomes. It has become my ‘go-to’ technique for the majority of my operative metacarpal fractures.”

Dr. David Shenassa (Sports Medicine Associates of South Florida, Fort Lauderdale, FL) concurs, stating “INnate is one of those rare products that combines surgeon-friendly, cost effective, and game-changing for our patients. Having a sports-focused surgery center in a very active patient population, I definitely see my fair share of metacarpal fractures.  Recently, I saw a high school senior who was actively being recruited by top NCAA programs for swimming; he sustained two metacarpal fractures during critical U.S. Nationals training. INnate allowed him to get back in the pool to train just three days post-op. Both he and I were very happy with the outcome. He’s now swimming for the University of Michigan.”

“5,000 successful INnate cases is a major achievement for ExsoMed. It further validates our approach in designing and developing innovative products and technologies for hand surgery,” said James Young Kim, ExsoMed’s Managing Director of Global Sales and Marketing. “For too long, innovation has been neglected in the hand surgery space, with subpar outcomes deemed acceptable for arguably the most vital human appendages. ExsoMed is here to change that. We believe our solutions will raise the standard of care in hand surgery by providing surgeons with user-friendly surgical tools that reduce the global cost of care and get patients back to work and daily activities faster.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”